Technology | Intellectual Property Position
AskBio is uniquely positioned to develop its BNPTM technology because of vital, patent protected intellectual properties developed by the founders and licensed exclusively to or acquired by the company. These inventions include:
AskBio has an issued patent in the United States for its Chimeric BNPs. As Chimerics are unique from any traditional AAV, based on the input of patent counsel, AskBio does not anticipate the need to obtain any intellectual property in order to have freedom to operate.
AskBio has multiple claims that have been allowed in the United States, Australia, Canada, Europe, and Japan. Askbio is expecting a patent to issue within the year.
AskBio has two broad issued patents in the United State with respect a purification process using heparin sulfate. This purification process is used by many AAV manufacturers, and each of them is required to obtain a license from us.
AskBio has several claims allowed for the use of AAV with support matrices, such as catheters, stents, and valves and expects a patent to issue.
AskBio acquired the mini-dystrophin gene from Dr. Xiao Xiao. AskBio has an issued patent in the United States for the Mini-dystrophin gene with additional claims in countries outside the U.S. pending.
In addition, AskBio has licensed HSV scalable grade production technology developed at the University of Florida for use in the treatment of Duchene's Muscular Dystrophy, with options for other fields of use.